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Abstract
Background: Midregional proadrenomedullin (MR-
proADM) is emerging as a prognostic biomarker for 
detecting the failure of multiple organs. Establishment of 
scientifically robust reference intervals facilitates inter-
pretation of laboratory test results. The objectives of this 
study were (i) to establish reliable reference intervals for 
plasma MR-proADM using a commercially available auto-
mated fluoroimmunoassay in apparently healthy indi-
viduals, and (ii) to identify biological determinants of MR-
proADM concentrations.
Methods: A total of 506 questionnaire-identified apparently 
healthy adults were enrolled in a single-center, cross-sec-
tional study. A final reference group (n = 172) was selected 
after exclusion of obese individuals, those with increased 
values of laboratory biomarkers indicating asymptomatic 
myocardial injury or dysfunction, ongoing inflammation, 
diabetes, dyslipidemia and renal dysfunction and outliers.
Results: The 2.5th and 97.5th percentile intervals for 
MR-proADM values in the reference group (90% confi-
dence interval) were 0.21 (0.19–0.23) and 0.57 (0.55–0.59) 
nmol/L, respectively. Although older age, higher values of 
HbA1c, C-reactive protein, B-type natriuretic peptide and 
body mass index, together with a history of smoking and 
a decreased estimated glomerular filtration rate were sig-
nificantly associated with increasing concentrations of 
MR-proADM in both univariate and multivariate analy-
ses, magnitudes of these relationships were modest and 
did not substantially influence MR-proADM reference 
intervals. Sex-dependent difference in MR-proADM ref-
erence intervals was not detected [0.19 (0.16–0.22)–0.56 
(0.54–0.60) nmol/L in females vs. 0.22 (0.20–0.25)–0.58 
(0.57–0.63) nmol/L in males].
Conclusions: Our study successfully established robust 
reference intervals for MR-proADM concentrations in 
plasma. Considering the negligible influence of poten-
tial biological determinants on plasma MR-proADM, we 
recommend the adoption of single reference intervals for 
adult population as a whole.
Keywords: MR-proADM; proadrenomedullin; reference 
intervals.
Introduction
Midregional proadrenomedullin (MR-proADM) is a reli-
able surrogate biomarker directly reflecting blood con-
centrations of unstable adrenomedullin (ADM). As ADM 
has been identified in a variety of tissues (i.e. heart, 
brain, lung, kidney, blood vessels, bone, adrenal cortex 
and adipose tissue), it may exhibit multiple biological 
functions due to its potent immunomodulatory, diuretic, 
bactericidal and vasodilatory activities [1]. MR-proADM is 
emerging as a promising biomarker for detecting possible 
organ failure, providing prognostic information as well 
as enabling multidimensional risk assessment in various 
subsets of patients [2]. Potential clinical applications of 
MR-proADM measurement include diagnosis and/or risk 
stratification in patients with suspected or established 
cardiovascular disorders (i.e. heart failure, various clini-
cal presentations of coronary artery disease and pulmo-
nary embolism), sepsis, lower respiratory tract infections, 
acute kidney injury or chronic kidney disease and other 
non-specific complaints [2, 3].
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An automated fluoroimmunoassay is commercially 
available (Brahms MR-proADM Kryptor, Thermo Fisher 
Scientific, Hennigsdorf, Germany) [4], but detailed studies 
on MR-proADM reference intervals and their biological 
determinants in healthy individuals are still sparse. MR-
proADM concentrations may vary substantially with age, 
renal function, inflammatory status and the presence of 
cardiovascular risk factors or subclinical coronary artery 
disease [3, 5–8]. Conflicting data exist regarding the impact 
of smoking status and sex on MR-proADM concentrations. 
Importantly, the majority of studies have been conducted 
in a variety of diseased populations or in unselected indi-
viduals from the general population. This emphasizes the 
need for a comprehensive study of MR-proADM reference 
values established in a well-characterized reference popu-
lation. Therefore, our aim was to establish reference inter-
vals for MR-proADM in plasma using the Kryptor system 
and to identify the biological determinants of concentra-
tions of this biomarker in a well-selected, homogenous 
healthy population.
Materials and methods
Study design and protocol
The study was designed as a community-based, cross-sectional 
study and included apparently healthy Caucasian individuals aged 
18–70 years, previously selected for similar projects involving meas-
urements of cardiac troponin I (measured with a highly sensitive 
assay, high-sensitivity cardiac troponin I [hs-cTnI]) and galectin-3 
[9–11]. The study protocol was approved by the Bioethics Committee 
of Nicolaus Copernicus University in Torun (Poland).
In detail, 640 potentially eligible individuals without any 
active or chronic inflammatory process, including infections, 
treatment with antibiotics, steroids, immunosuppressive agents 
or nonsteroidal anti-inflammatory drugs and/or pregnancy, were 
recruited in several workplaces in Bydgoszcz (Poland) between 
March and August 2013 and between July and August 2015. Prior 
to blood collection, all individuals signed a consent form and 
completed a predefined questionnaire (Supplemental Figure 1). A 
first screening applied to the entire population was based on the 
questionnaire and resulted in the exclusion of 107 subjects due to 
diabetes, hypertension or both. Following the further exclusion of 
27 individuals for whom data were not available, 506 presumably 
healthy individuals were finally enrolled in the study. The second 
screening aimed at selecting the reference group was resultant 
from the following laboratory tests and corresponding cutoffs for 
inclusion: hs-cTnI (Abbott Architect) <15.6 ng/L in females and 
<34.2 ng/L in males [9], B-type natriuretic peptide (BNP) (Abbott 
Architect) <35 ng/L [12], C-reactive protein (CRP) <10 mg/L [13, 14], 
glycated hemoglobin (HbA1c) <42  mmol/mol [15] and estimated 
glomerular filtration rate (eGFR) ≥90  mL/min/1.73  m2 [16]. Obese 
subjects were also excluded with body mass index (BMI) classified 
according to WHO criteria [17].
The flow diagram for the selection of reference group is shown 
in Figure  1. We used a direct selection approach for individuals as 
recommended by the CLSI EP28-A3c guidelines [18]. As detailed 
above, the baseline presumably healthy population composed of 
506  self-declared (by questionnaire) healthy subjects. Within the 
questionnaire-screened presumably healthy population, individu-
als were further categorized according to the above listed labora-
tory biomarker-based selection criteria. Obese individuals and those 
with high total cholesterol (TC) (≥6.22  mmol/L) and triglycerides 
(TG) (≥2.26 mmol/L) concentrations were also excluded [19]. Finally, 
after exclusion of four outliers (three women and one man with MR-
proADM concentrations of 1.14, 1.02, 0.96 and 1.12  nmol/L, respec-
tively), a well-selected, homogenous group of 172 individuals was 
used to derive MR-proADM reference intervals and further stratified 
to evaluate dependence of plasma MR-proADM concentrations from 
age and BMI.
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Figure 1: Flow diagram for the selection of the reference group.
BMI, body mass index; BNP, B-type natriuretic peptide; 
CRP,  C-reactive protein; HbA1c, glycated hemoglobin; hs-cTnI, cardiac 
troponin I measured with a highly sensitive assay; TC, total choles-
terol; TG, triglyceride; eGFR, estimated glomerular filtration rate; 
MR-proADM, midregional proadrenomedullin.
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Laboratory measurements
Blood samples were taken in fasting state and collected under stand-
ardized conditions. Serum and ethylenediaminetetraacetic acid 
(EDTA) plasma were separated from venous blood samples by centrif-
ugation for 10 min at 3000g at room temperature. Laboratory meas-
urements were performed in serum (creatinine, basic lipid profile, 
hs-cTnI), whole EDTA blood HbA1c and EDTA plasma BNP samples 
immediately following collection. All remaining plasma and serum 
samples were then aliquoted and stored at −70 °C until assayed for 
MR-proADM and CRP.
HbA1c, BNP, creatinine, TC, high-density lipoprotein cholesterol 
(HDL-C), TG and hs-cTnI were measured on the Abbott Architect 
ci8200 analyzer using commercially available assays (Abbott Labo-
ratories, Wiesbaden, Germany). Low-density lipoprotein cholesterol 
(LDL-C) concentrations were calculated using Friedewald’s equa-
tion, except for subjects with TG >2.26  mmol/L, for whom LDL-C 
was measured directly. Measurements of CRP were performed on the 
Horiba ABX Pentra 400 analyzer (Horiba ABX, Montpellier, France). 
eGFR was obtained using the Chronic Kidney Disease Epidemiology 
Collaboration equation [20].
EDTA plasma MR-proADM concentrations were measured using 
the fully automated fluoroimmunoassay on the Kryptor platform, 
with an assay range of 0.05–100  nmol/L. The between-run CV was 
≤20% in the range 0.1–0.3  nmol/L and <15% for concentrations 
>0.3 nmol/L [4].
Statistical analysis
Quantitative variables are expressed as medians and interquartile 
ranges, with categorical data as numbers and percentages. Quanti-
tative variables following the Gaussian distribution are presented as 
mean values ± SD. The Shapiro-Wilk test was used to assess the nor-
mality of distribution for investigated parameters. Depending on the 
presence or absence of normal distribution, comparisons between 
two unrelated groups were performed with the Student’s t-test for 
independent samples or the Mann-Whitney U-test, whereas the 
one-way analysis of variance or the Kruskal-Wallis test was applied 
for comparisons among more than two unrelated groups. Categori-
cal variables were compared using the chi-square test. Spearman’s 
rank correlation coefficient was used to test the associations between 
 MR-proADM concentrations and other continuous variables. The 
impact of potential determinants on variation in MR-proADM concen-
trations in plasma was evaluated with multivariable regression analy-
sis. MR-proADM concentrations were logarithmically transformed 
before their inclusion in this analysis to improve their adherence to 
normal distribution. The regression models used in our study, which 
included principally HbA1c, BNP and eGFR, were adjusted for age and 
sex together with hyperlipidemia; these followed adjustments for 
both BMI and smoking status. A two-sided p-value <0.05  was con-
sidered statistically significant. MR-proADM reference intervals were 
derived using a robust method as recommended in the CLSI EP28-A3c 
document [18]. Ninety percent confidence intervals were calculated 
for reference intervals. Outlier observations were excluded from the 
analyzed population by the method described by Grubbs, which is 
a double-sided method enabling identification of the most extreme 
value at either side [21]. Statistical analyses were performed using Sta-
tistica 13.0 for Windows (StatSoft, Tulsa, OK, USA) and MedCalc 17.9.2 
(MedCalc Software, Ostend, Belgium).
Results
Characteristics of the studied population
Table 1 summarizes baseline characteristics of the study 
population. The questionnaire-screened presumably 
healthy individuals had a higher median age than the 
Table 1: Baseline characteristics of the study population.
Variable   Presumably healthy 
population (n = 506)
  Reference group 
(n = 172)
  p-Value
Age, years   40 (32–51)   35 (30–41)   <0.0001
Sex, females   227 (55%)   86 (50%)   0.240
BMI, kg/m2   24.9 (22.0–27.9)   23.7 (21.4–25.8)   <0.0001
MR-proADM, nmol/L   0.41 (0.35–0.48)   0.39 (0.33–0.45)   0.0014
hs-cTnI, ng/L   2.4 (1.7–3.2)   2.1 (1.4–3.0)   0.110
BNP, ng/L   15 (10–24)   11 (10–18)   0.0002
HbA1c, mmol/mol   35.5 (32.2–38.8)   35.5 (32.0–37.7)   0.022
eGFR, mL/min/1.73 m2   94 (86–103)   99 (94–109)   <0.0001
TC, mmol/L   5.12 (4.49–5.95)   4.83 (4.31–5.35)   <0.0001
LDL-C, mmol/L   3.10 (2.50–3.80)   2.76 (2.30–3.36)   0.0008
HDL-C, mmol/L   1.45 (1.21–1.76)   1.47 (1.23–1.73)   0.893
TG, mmol/L   1.07 (0.78–1.62)   0.88 (0.68–1.20)   <0.0001
CRP, mg/L   0.53 (0.20–1.73)   0.32 (0.11–0.77)   <0.0001
Current or former smoker   141 (33%)   61 (38%)   0.06
Quantitative variables are expressed as medians and 1st–3rd quartile ranges and categorical data as numbers and percentages. BMI, body 
mass index; MR-proADM, midregional proadrenomedullin; hs-cTnI, cardiac troponin I measured with a highly sensitive assay; BNP, B-type 
natriuretic peptide; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; TC, total cholesterol; LDL-C, low-density lipopro-
tein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; CRP, C-reactive protein.
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reference individuals and significantly higher MR-proADM 
concentrations. Additionally, comparisons of the investi-
gated parameters revealed significantly higher values of 
BMI, BNP, HbA1c, TC, LDL-C, TG and CRP and lower eGFR 
values in the presumably healthy subjects. Although 
the distribution of sexes was comparable in both inves-
tigated groups, rates of smokers tended to be higher in 
Table 2: Spearman correlation coefficients between midregional 
proadrenomedullin and age, body mass index and laboratory 
parameters in the presumably healthy population (n = 506).
Variable RS p-Value
Age, years 0.343 <0.0001
BMI, kg/m2 0.394 <0.0001
hs-cTnI, ng/L 0.012 0.906
BNP, ng/L 0.164 0.0006
HbA1c, mmol/mol 0.038 0.403
eGFR, mL/min/1.73 m2 −0.257 <0.0001
TC, mmol/L 0.148 0.005
LDL-C, mmol/L 0.130 0.012
HDL-C, mmol/L −0.140 0.001
TG, mmol/L 0.288 <0.0001
CRP, mg/L 0.289 <0.0001
RS, Spearman correlation coefficient; BMI, body mass index; 
hs-cTnI, cardiac troponin I measured with a highly sensitive assay; 
BNP, B-type natriuretic peptide; HbA1c, glycated hemoglobin; eGFR, 
estimated glomerular filtration rate; TC, total cholesterol; LDL-C, 
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; TG, triglycerides; CRP, C-reactive protein.
Table 3: Impact of selected variables on log-transformed MR-proADM concentration in multiple regression analysis in the presumably 
healthy population (n = 506).
Regression models (all 
including HbA1c, BNP, eGFR)
  Model characteristics
Model adjusted for age and 
sexa
  R2 = 0.19
Significant determinants of log-transformed MR-proADM concentration: age (β = 0.007; p < 0.0001), sex 
(β = 0.099; p = 0.0001), eGFR (β = −0.003; p = 0.001) and CRP (β = 0.008; p < 0.0001)
Lack of impact: BNP and HbA1c
Model adjusted for age, 
sex and the presence 
hyperlipidemiaa
  R2 = 0.20
Significant determinants of log-transformed MR-proADM concentration: age (β = 0.007; p < 0.0001), sex 
(β = 0.096; p = 0.0002), eGFR (β = −0.003; p = 0.001) and CRP (β = 0.008; p < 0.0001)
Lack of impact: BNP, HbA1c and the presence of hyperlipidemia
Model adjusted for age, sex, 
hyperlipidemia, BMI and 
smoking statusa
  R2 = 0.29
Significant determinants of log-transformed MR-proADM concentration: age (β = 0.005; p = 0.0002), 
HbA1c (β = −0.006; p = 0.045), BNP (β = 0.001, p =0.036), eGFR (β = − 0.003; p = 0.001), CRP (β = 0.008; 
p < 0.0001), BMI (β = 0.020; p < 0.0001) and smoking (β = 0.092; p = 0.002)
Lack of impact: sex and the presence of hyperlipidemia
The presence hyperlipidemia was defined as coefficient values refer to a 1 unit increase of the investigated variables, if not otherwise stated. 
Males and females were coded as 1 and 0, respectively. Current or former smokers and non-smokers were coded as 1 and 0,  respectively. 
BMI, body mass index; BNP, B-type natriuretic peptide; CRP, C-reactive protein, eGFR, estimated glomerular filtration rate; HbA1c, glycated 
hemoglobin; HDL-C, high-density lipoprotein cholesterol; ap < 0.0001.
the reference group; however, a p-value did not reach the 
threshold of statistical significance. MR-proADM concen-
trations in plasma of reference group (n = 172) followed a 
normal distribution (Supplemental Figure 2).
Biological determinants of MR-proADM 
 concentrations in plasma
In univariate analysis, plasma MR-proADM concentrations 
were correlated with most investigated variables, except 
for hs-cTnI and HbA1c (Table 2). The highest Spearman cor-
relation coefficients were shown for BMI, age and CRP. To 
further examine relationships between log-transformed 
MR-proADM concentrations and independent covari-
ates, found to be significantly related to MR-proADM in 
univariate analysis, we developed multiple linear regres-
sion models. Models were initially adjusted for age, sex 
and hyperlipidemia, followed by adjustments for BMI 
and smoking. eGFR and CRP were significantly related to 
log-transformed MR-proADM concentrations after adjust-
ment for age, sex and the presence of hyperlipidemia 
(Table 3), and remained significantly associated with log-
transformed MR-proADM concentrations after adjustment 
for BMI and smoking habit. In the fully adjusted model, 
in addition to eGFR and CRP, also HbA1c, BNP, BMI and 
smoking habit were correlated with log-transformed MR-
proADM concentrations. Age significantly contributed to 
increased MR-proADM concentrations in all investigated 
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Table 4: Reference limits (with 90% confidence intervals) for 
 midregional proadrenomedullin concentrations in plasma.
Subgroup   n   2.5th Percentile, 
nmol/L
  97.5th Percentile, 
nmol/L
Overall   172   0.21 (0.19–0.23)   0.57 (0.55–0.59)
Males   86   0.22 (0.20–0.25)   0.58 (0.57–0.63)
Females   86   0.19 (0.16–0.22)   0.56 (0.54–0.60)
<40 years  120   0.19 (0.17–0.22)   0.57 (0.55–0.60)
≥40 years   52   0.24 (0.20–0.28)   0.60 (0.57–0.64)
Figure 2: Age- (A) and body mass index (B)-related midregional proadrenomedullin concentrations in plasma and reference intervals in the 
reference group (n = 172).
BMI, body mass index; MR-proADM, midregional proadrenomedullin.
regression models, whereas the effect of sex lost its statis-
tical significance in the fully adjusted model.
Reference intervals for MR-proADM 
 concentrations in plasma
Reference intervals for plasma MR-proADM concentra-
tions established in this study, also categorized according 
to sex as well as to age, are shown in Table 4. The derived 
limits were only slightly higher in males and older indi-
viduals. A visual inspection of continuously displayed 
2.5th and 97.5th percentile reference intervals for plasma 
MR-proADM, however, did not show any evident asso-
ciation with age (Figure 2A), with a modest though con-
stant rise with increasing BMI (Figure 2B). However, the 
MR-proADM reference interval derived from individuals 
with BMI <25 kg/m2 (n = 112) was 0.20–0.55 nmol/L, there-
fore comparable to that obtained for all reference group 
(0.21–0.57 nmol/L).
Outlier results
We reassessed the concentrations of MR-proADM in all 
four outliers and obtained exactly the same results as 
those initially reported in the manuscript. Therefore, 
we do not consider them to be analytical outliers. We 
attempted to contact all four persons with outlier concen-
trations. Six months after completion of the study, one 
participant suffered from hypothyreosis which is now well 
controlled. This subject had not experienced any other 
adverse events at the 24 month follow-up. Unfortunately, 
we were unable to contact the three other persons present-
ing outlier concentrations.
Discussion
Establishment of robust reference intervals facilitates 
the interpretation of laboratory test results. In our cross-
sectional study, we have successfully established reli-
able reference intervals for MR-proADM concentrations 
in plasma, using predefined selection criteria to identify 
a healthy reference group. In order to achieve this goal, 
we applied a health questionnaire combined with labora-
tory biomarkers screening. Although HbA1c, CRP and BMI, 
together with a history of smoking and eGFR, remained 
significantly associated with concentrations of MR-
proADM, magnitudes of these relationships were modest 
and did not substantially influence reference intervals 
for MR-proADM in plasma. Notably, the reference values 
for MR-proADM in our study were comparable between 
females and males.
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MR-proADM plasma concentrations measured in our 
reference group are comparable to those originally pro-
vided by Caruhel et al. [4] and then reported by Brahms 
in the assay package insert (median: 0.39 nmol/L; 97.5th 
percentile: 0.55  nmol/L), but slightly lower than those 
reported by Smith et  al. (median: 0.41  nmol/L; 97.5th 
percentile: 0.64  nmol/L and 0.66 in men and women, 
respectively) [8]. However, this study preferentially used 
clinical and less tightened laboratory-based exclusion cri-
teria (e.g. eGFR <60 mL/min/1.73 m2 and CRP >20 mg/L), 
whereas the selection of our reference individuals was 
based on more stringent criteria, which may account for 
slightly lower MR-proADM plasma concentrations in the 
reference group and consequently in derived reference 
intervals.
The biological determinants of MR-proADM plasma 
concentrations found in our study are similar to those 
previously reported [5, 8]. In contrast to our project, 
however, prior studies included unselected subjects. 
In participants of the Malmö Diet and Cancer study 
(n = 5258), Smith et  al. [8] demonstrated increasing 
values of age, BMI, body fat percentage, TC, LDL, TG, 
HbA1c, CRP, N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), cystatin C and alcohol intake, together with 
current smoking, as independent determinants of MR-
proADM plasma concentrations. However, a large major-
ity of these parameters were only weakly associated with 
MR-proADM plasma concentrations. The strongest inde-
pendent association was shown for cystatin C, which 
accounted for 18% of MR-proADM variability in the mul-
tivariate model [8]. In their study involving 1002 elderly 
individuals from the general community, Eggers et  al. 
[5] found that MR-proADM was independently related to 
current smoking, renal dysfunction, obesity, lower left-
ventricular ejection fraction and higher concentrations 
of NT-proBNP and CRP.
Despite the recognized potential for the clinical appli-
cation of this biomarker, detailed mechanisms explaining 
how biological determinants may influence MR-proADM 
concentrations are not fully understood. The association 
of MR-proADM with renal function could reflect the clear-
ance of MR-proADM molecule from circulation by renal 
emunctory [8]. In patients with chronic kidney disease, 
Dieplinger et  al. [22] demonstrated a strong correlation 
between MR-proADM concentrations and the glomeru-
lar filtration rate measured by iohexol clearance (−0.82; 
p < 0.001). The relationship between MR-proADM and 
both BMI and HbA1c may in turn reflect the influence of 
overweight/obesity or metabolic syndrome on ADM syn-
thesis. In line with this assumption, increased expression 
of ADM was observed in the adipose tissue of obese vs. 
lean women [23]. Moreover, ADM may also directly inhibit 
insulin secretion [24] and lead to insulin resistance [25]. 
Additionally, an accumulating body of evidence indicates 
that inflammation triggers ADM synthesis [26, 27], which 
may explain the positive correlation between CRP and MR-
proADM found in our study. Finally, we can also speculate 
that smoking may cause subclinical arthrosclerosis result-
ing in higher MR-proADM concentrations.
Elevated MR-proADM concentrations may reflect the 
failure of multiple organs, which translates into poten-
tially broad clinical indications for MR-proADM testing 
[2]. However, this biomarker remains non-specific, and 
therefore, interpretation of a result needs to be integrated 
with careful clinical assessment and other examinations. 
Our study was conducted with a rigorous methodology 
and a direct approach. Its strength lies in the selection 
and definition of a healthy reference group, the applica-
tion to this well-defined cohort of standardized labora-
tory measurements and clinically validated cutoffs, the 
employment of appropriate statistical methods and the 
identification of major biological determinants of plasma 
MR-proADM concentrations. Some limitations of our 
study should be mentioned. First, due to the nature of 
our single center study and identification of 2.3% of the 
already-prescreened population as statistical outliers, 
our findings warrant verification in larger studies with 
a clinical follow-up. The presence of outlier values may 
potentially affect the prognostic power of MR-proADM 
assays. Second, our study protocol did not include 
cardiac imaging examinations. However, the cutoff value 
for BNP used in our study was previously shown to suc-
cessfully exclude patients with both heart failure and left 
ventricular dysfunction [12]. Third, we did not assess cys-
tatin C, insulin resistance and abdominal adipose tissue, 
other potential determinants of MR-proADM concentra-
tions in blood. Fourth, the measurement of MR-proADM 
was conducted on samples that were initially stored in a 
frozen state. However, this does not substantially affect 
the accuracy of our results due to the validated stability 
of MR-proADM [28].
In conclusion, our study successfully established reli-
able reference intervals for MR-proADM concentrations in 
plasma. Considering the negligible influence of potential 
biological determinants on MR-proADM concentrations, 
we recommend the adoption of single reference intervals 
for adult population as a whole.
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